A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Clinical trial NCT02135133 · COMPLETED

Trial details

NCT number: NCT02135133
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2014-06-01
Primary completion: 2020-10-06
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.